MicroRNA-153 may act as a potential biomarker and prognostic indicator of patients with gastric cancer

MicroRNA (miR/miRNA)-153, as a novel tumor-related miRNA, has been found to be aberrantly expressed in different types of cancer; however, to the best of our knowledge, the role of miR-153 in gastric cancer (GC) remains unclear. The present study demonstrated that miR-153 expression was markedly decreased in GC, including GC cell lines and culture medium, GC tissues, and serum samples, based on reverse transcription-quantitative PCR, and this was further confirmed by fluorescence in situ hybridization. Transfection with miR-153 mimics inhibited proliferation and migration, and promoted apoptosis in GC cells. The serum expression levels of miR-153 were decreased in 59 patients with GC compared with those of 9 healthy controls, and more decreased in advanced GC compared with early-stage GC, suggesting that miR-153 was associated with tumor progression. Furthermore, serum miR-153 was expressed at significantly lower levels in patients with GC with larger tumor size (>= 4 cm; P=0.013), poor differentiation and signet histology (P=0.013), lymph node metastasis (P=0.025) and advanced tumor stage (TNM stage III and IV; P=0.048) compared with patients with a smaller tumor size (<4 cm), well and moderate differentiation, no lymph node metastasis, and TNM stage I and II, respectively. In conclusion, the present study revealed that low miR-153 expression was associated with poor prognosis in GC and miR-153 may potentially act as a tumor biomarker and therapeutic target in GC.

Automated summary

MicroRNA-153 (miR-153), a novel tumor-related miRNA, is aberrantly expressed in gastric cancer (GC). The study showed that miR-153 expression is significantly decreased in GC cells, tissues, and serum samples. Transfection with miR-153 mimics inhibits GC cell proliferation and migration, while promoting apoptosis. The serum expression levels of miR-153 are lower in patients with larger tumor size, poor differentiation, lymph node metastasis, and advanced tumor stage. These findings suggest that miR-153 may serve as a potential tumor biomarker and therapeutic target in GC.